Catherine Pagliarulo
Vice President, Life Science at Alexandria Real Estate Equities
Greater Boston
Overview
Work Experience
Vice President, Life Science
2021 - Current
Alexandria Venture Investments
Principal, Science & Technology
2019 - 2020
Alexandria Venture Investments
Senior Associate, Science & Technology
2018 - 2019
Alexandria Venture Investments
Associate, Science & Technology
2017 - 2017
Alexandria Venture Investments
Senior Research Analyst, Science & Technology
2015 - 2016
Alexandria Venture Investments
Alexandria Real Estate Equities is a strategic venture capital arm of Alexandria Real Estate Equities.
Board Observer
2019
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.
Raised $189,320,327.00 from 8VC, ARCH Venture Partners, Alexandria Venture Investments, Moore Strategic Ventures, Newpath Management, Hatteras Venture Partners, Hatteras Venture Partners, Alexandria Venture Investments and 8VC.
Research Associate II, Discovery Chemistry
2010 - 2015
Medicinal Chemistry: Key contributor to ion channel project: Synthesized analogs for several chemical series; optimized targets for potency, solubility and microsomal stability; proposed new analogs based on data using virtual tools and presented ideas at team meetings. Developed strong understanding of multi-disciplinary drug discovery programs. Business Development Job Rotation Marketing Job Rotation
Research Intern, Medicinal Chemistry
2009 - 2009
Schering-Plough Corporation is a major U.S.-based manufacturer of pharmaceuticals.
Research Assistant, Chemistry Department
2008 - 2008
Explored the design and synthesis of anthracene derived phosphine ligands for improvement of asymmetric diboration reactions